TSO3 — Investor Presentation (April 2012)
49 slides from TSO3's investor presentation, April 2012
Slide 1: Corporate presentation
Corporate presentation Updated Q1 2012 (as of March 31) Creating the Improved Standard in Healthcare Sterile Reprocessing
Slide 2: Company Overview
Company Overview • Founded 1998 • Designed and manufactured a low temperature sterilizer for medical devices • IPO 2001 • TSX: TOS • 59M shares outstanding
Slide 3: Key Events Under Initial Management
Key Events Under Initial Management 2002 • Received HC Authorization for first generation sterilizer (125L) 2003 • Received FDA Clearance for first generation sterilizer (125L) 2006 • Received FDA Clearance for additional claims to include rigid lumened instruments (125L) 2008 • TSO3 total 38 placem
Slide 4: Renewed Leadership
Renewed Leadership • R.M. (Ric) Rumble, CEO – Joined October 2008 – More than 25 years experience within the North American and Global medical device industry, capital and consumables – Business Unit Manager, Sterility Assurance – 3M – President - MediVators Inc – VP & GM – Global Healthcare Sterili
Slide 5: Recent Key Events
Recent Key Events • Adopts new and aggressive strategic plan in order to increase utility of sterilizer • Freezes design of new generation (STERIZONE® 125L+) sterilizer offering increased compatibility and speed 2009 • Signs global channel partner agreement with 3M™ for new generation sterilizer (TS
Slide 6: Our Vision: To Create the Improved Standard in Healthcare
Our Vision… To Create the Improved Standard in Healthcare Sterile Reprocessing
Slide 7: Opportunity
Opportunity Medical Sterile Reprocessing of Reusable Instruments 7
Slide 8: In business to win
In business to win The Product/ Solution The Market The Channel
Slide 9: Why low temperature sterilization?
Why low temperature sterilization?
Slide 10: Market Drivers
Market Drivers 10
Slide 11: Growing Population
Growing Population 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 12: Aging Population
Aging Population 60 53% 50 increase 65 yrs + 40 45 to 64 % Increase 15 to 44 30 - 15 yrs 20 10 0 2001 2005 2010 2015 2020 65 yrs+ is the fastest growing segment Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 13: Impact of Age on Demand for Surgery
Impact of Age on Demand for Surgery 88% of ophthalmology surgeries Number of 70% of cardiothoracic surgeries procedures (average) 65% of urology surgeries 60% of general surgeries Age 45 55 65 75 As we age, we require more OR time Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 14: Advancement in Medical Techniques
Advancement in Medical Techniques From Traditional Open Surgery To Minimally Invasive Surgery (MIS) 14
Slide 15: 30 million MIS Procedures
MIS Procedures Increasingly used and finding new applications everyday Orthopaedic Neurosurgery Pulmonary medicine 30 million MIS Gynaecology surgeries in US/year Urology Gastrointestinal Cardiology 15 The National Institute of Health (NIH).
Slide 16: MIS Devices are Complex & Delicate
MIS Devices are Complex & Delicate $50k Colonoscope 16
Slide 17: MIS Devices require low temperature sterilization
MIS Devices require low temperature sterilization
Slide 18: Sterilization Areas in Hospitals
Sterilization Areas in Hospitals 2 OR 1 CS OR OR OR OR Central Sterilization (CS) Operating Room Department (OR) Low Temperature Sterilization OR OR OR OR Gas Liquid OR Reprocessing and Sterile Storage Steam Sterilization 3 GI Gastrointestinal Department (GI) Liquid 18
Slide 19: Customers want Throughput
Customers want THROUGHPUT TSO3 sterilizer conjoint study July 2009 - Allegheny Marketing Group.
Slide 20: Available Sterilization Solutions
Available Sterilization Solutions Ethylene Oxyde Hydrogen Peroxide Liquid Hyg. Per. + Ozone (EtO) (H2O2) Peracetic Acid (PAA) (H2O2/O3) Efficacious Fast Specific use in OR Fast High material Limited in Liquid = Not terminal Efficacious compatibility efficacy sterilization Long cycles Limited in Repl
Slide 21: Our Technology Enables Throughput
Our Technology Enables Throughput By combining: • Efficacy & Compatibility • High loading capacity • Speed 21
Slide 22: Market Overview / Low Temperature Sterilization
Market Overview / Low Temperature Sterilization • Capital equipment business Worldwide Installed Base – Low temperature gas sterilizers in hospitals: • ~26,000 installed worldwide • Life span ~ 12 years US • Replacement business: 2,000 units/year Canada Europe • Consummables business ROW – Estimated
Slide 23: A Winning Channel Partner
A Winning Channel Partner • Innovative • Customer respected • Leading competitor in space • Globally established
Slide 24: 3M Global Reach
3M Global Reach TaN Ka " ; - }
Slide 25: Activities and Results
Activities and Results 25
Slide 26: Key Strategic Activities
Key Strategic Activities • Regulatory • Commercial • Enhanced Portfolio 26
Slide 27: Regulatory Status USA
Regulatory Status USA • Changing regulatory environment / request to re-file through new process • Re-filed June 30, 2011 • Subsequent additional data requested by Agency - filed April 20, 2012 Active file in progress - 11 months through the process 27
Slide 28: What is moving through the US Regulatory Process from TSO3?
What is moving through the US Regulatory Process from TSO3? Biological Indicator (BI) Process Indicator (CI) Test Pack Sterile Efficacy Validation Sterilizer 28
Slide 29: General Nature of Questions
General Nature of Questions Cycle 1 Monitoring Methods Cycle 2 Cycle 3 Demonstrating that same indicators effectively monitor cycles with different configurations 29
Slide 30: Commercial launch 3M / TSO3
Commercial launch 3M / TSO3 • Initiated phased global roll-out June 2011, based on regulatory clearances: – Health Canada clearance - Obtained – CE Mark for European Union - Obtained • 2011: – Product introduced in 11 countries second-half of the year (including APAC Region) (planned 15) – Executed
Slide 31: 3M Product Positioning
3M Product Positioning • “Ingenious solution to low temperature sterilization challenges” • “Has better lumen penetration and can process multiple flexible endoscopes in a single load” • “Has a larger capacity and provides better daily throughput compared to any other low temperature sterilizer” • “
Slide 32: 3M Worldwide Optreoz Sterilizer Web App
3M Worldwide Optreoz® Sterilizer Web App 32 Courtesy of 3M.
Slide 33: 3M Marketing and Sales Collateral
3M Marketing and Sales Collateral 33 Courtesy of 3M.
Slide 34: Positioning in Exhibits
Positioning in Exhibits 34 Courtesy of 3M.
Slide 35: Customer Feedback
Customer Feedback • “Improving our standard of care by terminally sterilizing devices previously reprocessed using a liquid chemical sterilization method” • “Virtually eliminated the use of the liquid process, as flexible scopes are now terminally sterilized, along with additional devices” • “Runnin
Slide 36: Preparing to Ramp
Preparing to Ramp 36
Slide 37: Market Potential
Market Potential 37
Slide 38: Revenues on Unit Sale over 10-year
Revenues on Unit Sale over 10-year End-User Price $ 640k $480k $320k Margins $160k 1 2 3 4 5 6 7 8 9 10 Year 38
Slide 39: Next Product: STERIZONE 80L Sterilizer
Next Product • STERIZONE® 80L Sterilizer • Market : OR Sub-Sterile Area • Inventory limitations, flexibility in schedule, shorter turn-around time • Potential placements (NA): > 7,500 units • 50% of customers surveyed want the product Features • Multiple devices in same load • Mix of lumened and sur
Slide 40: STERIZONE 80L Sterilizer
STERIZONE® 80L Sterilizer 40
Slide 41: Looking Towards the Future
Looking Towards the Future 41
Slide 42: Our Positioning
Our Positioning English Francais +86, Creating the improved Standard = in Heatthcare Sterilization Reprocessing™ News & Events About Contact Careers —— | TE, cement Why levest? TOS:TSX « 17.89 +0.40 (+219%) he! ee Investment Strategy cooncateepoany VEDCASt and — Performance reporting to keep imestor
Slide 43: Our Strengths
Our Strengths • Rapid research & prototyping – Small and flexible structure – Tunable technology • Sterilization testing expertise – Microbiology – Materials compatibility testing • Positive regulatory track record • Licensing-out 43
Slide 44: Strategy
Strategy • Obtain required regulatory clearances – United States (Optreoz™ 125-Z) – Global (80L) • Increase portfolio – New development – Acquisitions – Joint ventures • Maintain focus on current space – Medical sterile reprocessing 44
Slide 45: Creating Value
Creating Value • Our offering – Technology and competency based • Our targets – Medical device manufacturers – Sales channels – Investors • Our tactics – Web based – OEM channel 45
Slide 46: What to Expect in 2012?
What to Expect in 2012 ? • US Regulatory Agency follow-up/clearance on filing for 3M™ OPTREOZ™ 125-Z Sterilizer • Initiate regulatory filings for clearance to sell new OR product (Q3) • Initial commercial activities on the OR product in cleared countries (Q4) 46
Slide 47: Financial Situation – As of March 31
Financial Situation – As of March 31 Q1 2012 (000’s) Sales & License Revenues 780 Cash, Cash Equivalents & Temporary Investments 9,856 Inventories 885 Total Assets 16,607 Shareholder’s Equity 13,751 Monthly Burn Rate *692 Shares Outstanding 58,786 Options Outstanding 3,751 *After adjustment to elimi
Slide 48: Investment Highlights
Investment Highlights Large and growing market Superior technology meets customer needs Strong global channel partner Pursuing new applications and opportunities Financially sound 48
Slide 49: © TSO3 Inc., 2012. All rights reserved.
© TSO3 Inc., 2012. All rights reserved. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc. - OZO-TEST® - STERIZONE® are Reg. U.S. Pat. & Tm. Off. TSO3 STERIZONE® Sterilizer U.S. Pat. No. 7,128,872 / 7,582,257 / 7